TWI719938B - 多重細菌感染之治療 - Google Patents

多重細菌感染之治療 Download PDF

Info

Publication number
TWI719938B
TWI719938B TW104119861A TW104119861A TWI719938B TW I719938 B TWI719938 B TW I719938B TW 104119861 A TW104119861 A TW 104119861A TW 104119861 A TW104119861 A TW 104119861A TW I719938 B TWI719938 B TW I719938B
Authority
TW
Taiwan
Prior art keywords
seq
antibody
antigen
pseudomonas aeruginosa
amino acid
Prior art date
Application number
TW104119861A
Other languages
English (en)
Chinese (zh)
Other versions
TW201613575A (en
Inventor
布里特 希爾曼
詹姆西 強森 西里爾德
歐馬利 瓊斯
查理斯 肯 史多夫
Original Assignee
美商麥迪紐有限責任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商麥迪紐有限責任公司 filed Critical 美商麥迪紐有限責任公司
Publication of TW201613575A publication Critical patent/TW201613575A/zh
Application granted granted Critical
Publication of TWI719938B publication Critical patent/TWI719938B/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1214—Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW104119861A 2014-06-19 2015-06-18 多重細菌感染之治療 TWI719938B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462014506P 2014-06-19 2014-06-19
US62/014,506 2014-06-19
US201562140849P 2015-03-31 2015-03-31
US62/140,849 2015-03-31

Publications (2)

Publication Number Publication Date
TW201613575A TW201613575A (en) 2016-04-16
TWI719938B true TWI719938B (zh) 2021-03-01

Family

ID=54936121

Family Applications (1)

Application Number Title Priority Date Filing Date
TW104119861A TWI719938B (zh) 2014-06-19 2015-06-18 多重細菌感染之治療

Country Status (11)

Country Link
US (1) US11168132B2 (enExample)
EP (1) EP3157565B1 (enExample)
JP (2) JP6845016B2 (enExample)
KR (1) KR102549870B1 (enExample)
CN (1) CN106456767B (enExample)
AU (1) AU2015276938B2 (enExample)
CA (1) CA2952278A1 (enExample)
ES (1) ES2983252T3 (enExample)
SG (2) SG11201609652RA (enExample)
TW (1) TWI719938B (enExample)
WO (1) WO2015196011A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12492243B2 (en) 2016-05-05 2025-12-09 The Trustees Of The University Of Pennsylvania DNA antibody constructs for use against Pseudomonas aeruginosa

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2838211C (en) 2011-06-10 2023-08-01 Medimmmune Limited Anti-pseudomonas psl binding molecules and uses thereof
HUE050985T2 (hu) 2011-11-07 2021-01-28 Medimmune Ltd Pseudomonas PSL és PCRV elleni kötõmolekulát alkalmazó kombinációs terápiák
KR20150092738A (ko) 2012-11-06 2015-08-13 메디뮨 엘엘씨 에스.아우레우스 연관 질병의 치료 방법
CN104968797B (zh) * 2012-11-06 2018-11-30 米迪缪尼有限公司 金黄色葡萄球菌表面决定簇的抗体
EP3383884A4 (en) 2015-11-30 2019-07-31 Medimmune Limited PROCESS FOR PREVENTING OR TREATING NOSOCOMIAL PNEUMONIA
TWI781130B (zh) 2017-01-03 2022-10-21 美商再生元醫藥公司 抗金黃色葡萄球菌溶血素ａ毒素之人類抗體
TWI902669B (zh) 2018-07-24 2025-11-01 美商麥迪紐有限責任公司 抗金黃色葡萄球菌凝集因子a(clfa)之抗體
WO2020076789A2 (en) 2018-10-09 2020-04-16 Medimmune, Llc Combinations of anti-staphylococcus aureus antibodies
EP3864040A1 (en) 2018-10-09 2021-08-18 Medimmune, LLC Antibodies directed against staphylococcus aureus leukotoxins
GB201816554D0 (en) 2018-10-10 2018-11-28 Centauri Therapeutics Ltd Novel compounds and therapeutic uses thereof
GB201816553D0 (en) 2018-10-10 2018-11-28 Centauri Therapeutics Ltd Novel compounds and therapeutic uses thereof
WO2020172233A1 (en) * 2019-02-22 2020-08-27 The Trustees Of Columbia University In The City Of New York Treatment of prostate cancer by androgen ablation and il-8 blockade
TW202100549A (zh) * 2019-03-13 2021-01-01 美商麥迪紐有限責任公司 降低金黃色葡萄球菌在定殖的患者中之感染
CN113966343A (zh) * 2019-06-11 2022-01-21 瑞泽恩制药公司 结合PcrV的抗PcrV抗体、包含抗PcrV抗体的组合物及其使用方法
US20220259290A1 (en) * 2019-07-24 2022-08-18 Japan Science And Technology Agency Innovative production technique for antibody-enzyme
FR3114970B1 (fr) * 2020-10-08 2023-06-30 Univ Tours Combinaison d’anticorps inhalés avec des agents immunomodulateurs pour le traitement ou la prévention d’inféctions respiratoires
WO2025117765A1 (en) * 2023-12-01 2025-06-05 University Of Washington Protective monoclonal antibodies to pseudomonas aeruginosa

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110165172A1 (en) * 2009-12-22 2011-07-07 Kalobios Pharmaceuticals, Inc. Method of treating a staphylococcus infection in a patient having a low-level pathogenic pseudomonas aeruginosa infection
CN103443285A (zh) * 2011-02-08 2013-12-11 米迪缪尼有限公司 特异性结合金黄色葡萄球菌α毒素的抗体以及使用方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2719397A1 (en) 2006-06-12 2014-04-16 GlaxoSmithKline Biologicals SA Use of alpha-toxin for treating and preventing staphylococcus infections
HUE050985T2 (hu) * 2011-11-07 2021-01-28 Medimmune Ltd Pseudomonas PSL és PCRV elleni kötõmolekulát alkalmazó kombinációs terápiák
KR20150092738A (ko) 2012-11-06 2015-08-13 메디뮨 엘엘씨 에스.아우레우스 연관 질병의 치료 방법
CN104968797B (zh) 2012-11-06 2018-11-30 米迪缪尼有限公司 金黄色葡萄球菌表面决定簇的抗体
KR20150082367A (ko) * 2012-11-06 2015-07-15 메디뮨 엘엘씨 항슈도모나스 ｐｓｌ 및 ｐｃｒｖ 결합 분자를 이용한 병용 요법
WO2017075188A2 (en) 2015-10-30 2017-05-04 Medimmune, Llc Methods of using anti-alpha toxin antibody

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110165172A1 (en) * 2009-12-22 2011-07-07 Kalobios Pharmaceuticals, Inc. Method of treating a staphylococcus infection in a patient having a low-level pathogenic pseudomonas aeruginosa infection
CN103443285A (zh) * 2011-02-08 2013-12-11 米迪缪尼有限公司 特异性结合金黄色葡萄球菌α毒素的抗体以及使用方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Mashburn LM et al., J Bacteriol. 2005 Jan;187(2):554-66. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12492243B2 (en) 2016-05-05 2025-12-09 The Trustees Of The University Of Pennsylvania DNA antibody constructs for use against Pseudomonas aeruginosa

Also Published As

Publication number Publication date
US11168132B2 (en) 2021-11-09
CN106456767B (zh) 2021-07-09
JP2017519768A (ja) 2017-07-20
AU2015276938A1 (en) 2017-01-05
CA2952278A1 (en) 2015-12-23
CN106456767A (zh) 2017-02-22
SG11201609652RA (en) 2016-12-29
TW201613575A (en) 2016-04-16
KR20170015329A (ko) 2017-02-08
US20170129943A1 (en) 2017-05-11
AU2015276938B2 (en) 2020-11-19
WO2015196011A1 (en) 2015-12-23
KR102549870B1 (ko) 2023-06-29
EP3157565A1 (en) 2017-04-26
EP3157565B1 (en) 2024-04-24
EP3157565A4 (en) 2018-03-21
JP2021063090A (ja) 2021-04-22
JP6845016B2 (ja) 2021-03-17
ES2983252T3 (es) 2024-10-22
SG10201811361XA (en) 2019-01-30

Similar Documents

Publication Publication Date Title
TWI719938B (zh) 多重細菌感染之治療
US11447543B2 (en) Antibodies to S. aureus surface determinants
EP2464665B1 (en) Human monoclonal antibody against s. aureus derived alpha-toxin and its use in treating or preventing abscess formation
TWI861227B (zh) 抗α-溶血素的抗體及其應用
KR20210072057A (ko) 항-황색포도상구균 항체의 조합
HK1236126B (en) Treatment of polybacterials infections
HK1236126A1 (en) Treatment of polybacterials infections
RU2808018C2 (ru) Антитела к поверхностным детерминантам s. aureus
HK1215452B (zh) 金黃色葡萄球菌表面決定簇的抗體